{
    "clinical_study": {
        "@rank": "38659", 
        "acronym": "PALP-COPD", 
        "arm_group": [
            {
                "arm_group_label": "mechanical ventilation (MV)", 
                "arm_group_type": "No Intervention", 
                "description": "mechanical ventilation according to guidelines"
            }, 
            {
                "arm_group_label": "MV + ECCO2-R(PALP-Device/MaquetCP)", 
                "arm_group_type": "Experimental", 
                "description": "MV according to the guidelines plus CO2-Removal with PALP"
            }
        ], 
        "brief_summary": {
            "textblock": "A Multicenter, Randomized, Controlled Trial to Determine Safety and Efficacy of Pump\n      Assisted Lung Protection (PALP\u2122) for Low Flow Carbon Dioxide (CO2) Removal in Conjunction\n      with Liberation from Mechanical Ventilation Compared to Mechanical Ventilation Alone in\n      Patients with COPD Exacerbation and Respiratory Failure"
        }, 
        "brief_title": "The PALP\u2122-COPD Trial (Low-Flow CO2-Removal (ECCO2-R) in Exacerbated COPD)", 
        "completion_date": {
            "#text": "December 2016", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "COPD", 
            "Chronic Obstructive Pulmonary Disease"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Lung Diseases", 
                "Respiration Disorders", 
                "Pulmonary Disease, Chronic Obstructive", 
                "Lung Diseases, Obstructive"
            ]
        }, 
        "detailed_description": {
            "textblock": "Primary Study Objectives\n\n      \u2022 To evaluate the clinical effect of PALP\u2122 in reducing the time on invasive ventilation in\n      patients with an exacerbation of COPD requiring invasive mechanical ventilation.\n\n      Secondary Study Objectives\n\n        -  To evaluate the safety and tolerability of PALP\u2122 in patients with an exacerbation of\n           COPD requiring invasive mechanical ventilation.\n\n        -  To determine if rates of adverse events (AEs) are reduced in patients who receive PALP\u2122\n           and invasive mechanical ventilation vs invasive mechanical ventilation alone.\n\n        -  To determine mortality rates in patients who receive PALP\u2122 and invasive mechanical\n           ventilation vs invasive mechanical ventilation alone.\n\n        -  To determine if PALP\u2122 will effectively reduce the number of subsequent acute\n           decompensations requiring hospital admission for ventilatory support (invasive or\n           noninvasive)."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          1. Male or female, and \u226540 years of age\n\n          2. Known history of COPD\n\n          3. Currently experiencing an exacerbation of COPD\n\n          4. P/F ratio >150 mmHg\n\n          5. Currently endotracheally intubated and requiring invasive mechanical ventilation\n             (must have been on invasive mechanical ventilation for 24-48 hours)\n\n          6. Able to tolerate large bore intravenous (IV) cannulation required for proper\n             operation of study device\n\n          7. For female patients of child-bearing potential, a negative urine or serum pregnancy\n             test at screening; all female patients will be considered of child-bearing potential\n             unless they are post menopausal for at least 1 year or have been surgically\n             sterilized (bilateral tubal ligation, bilateral oophorectomy, or hysterectomy)\n\n          8. Written informed consent obtained according to local regulations; or, if unable to\n             provide written informed consent due to incapacitation, a legally authorized\n             representative is able to provide written informed consent on behalf of the patient\n\n        Exclusion Criteria:\n\n          1. Any end-stage medical conditions with expected survival <6 months\n\n          2. Tracheostomy\n\n          3. Unable to provide central venous access\n\n          4. Acute brain injury\n\n          5. Any legally authorized document(s) that may restrict aggressive medical management\n             such as \"Do Not Resuscitate,\" \"Do Not Intubate,\" etc.\n\n          6. Risk of bleeding or clotting such as:\n\n               -  Known bleeding diathesis or abnormal clotting\n\n               -  Recent or current use of medications known to increase risk of bleeding\n\n          7. Screening platelet count of <75,000/mm3 or international normalized ratio (INR) >1.5\n             or activated partial thromboplastin time (aPTT) >1.5 times the upper limit of normal\n             (ULN) range for their respective laboratory values\n\n          8. Any recognized contra indications to systemic anticoagulation therapy or use of\n             heparin\n\n          9. Body mass index (BMI) >35\n\n         10. Any form of chronic hyperventilation not related to COPD\n\n         11. Hemodynamic instability  or requiring significant vasopressor support\n\n         12. Cardiogenic or noncardiogenic pulmonary edema as the primary reason for respiratory\n             failure\n\n         13. High risk cardiac conditions\n\n         14. Oxygen tension in arterial blood (PaO2) <50 mmHg via arterial blood gas (ABG) or any\n             condition in which hypoxemia is a significant component of the respiratory failure\n\n         15. Any other medical cause for acute respiratory failure not directly related to a COPD\n             exacerbation\n\n         16. Use of or treatment with an investigational drug, therapy, or device within 1 month\n             (30 days) of baseline\n\n         17. Female patients who are pregnant or breastfeeding\n\n         18. Patients who are immuno-compromised\n\n         19. Current active malignancy or history of malignancy within the past 5 years\n\n         20. Patients in chronic dialysis\n\n         21. Patients requiring extra-corporeal life support (ECLS) as a bridge to transplant\n\n         22. Patients who, in the opinion of the investigator, would not be able to comply with\n             the requirements of the study"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "120", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "March 28, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02107222", 
            "org_study_id": "MAQ/COPD/PALP/2012"
        }, 
        "intervention": {
            "arm_group_label": "MV + ECCO2-R(PALP-Device/MaquetCP)", 
            "description": "extracorporeal circuit to remove CO2 out of the blood", 
            "intervention_name": "CO2-Removal (PALP-Device/MaquetCP)", 
            "intervention_type": "Device"
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "COPD", 
            "Exacerbation", 
            "invasive ventilation", 
            "CO2-Removal"
        ], 
        "lastchanged_date": "April 4, 2014", 
        "location": {
            "facility": {
                "address": {
                    "city": "Rastatt", 
                    "country": "Germany", 
                    "zip": "76437"
                }, 
                "name": "MAQUET Cardiopulmonary AG"
            }, 
            "status": "Not yet recruiting"
        }, 
        "location_countries": {
            "country": "Germany"
        }, 
        "number_of_arms": "2", 
        "official_title": "A Multicenter Randomized Control Trial (RCT) to Determine Safety and Efficacy of PALP\u2122 for ECCO2-R in Conjunction With Liberation From Mechanical Ventilation (MV) Compared to MV Alone in COPD Exacerbation and Respiratory Failure", 
        "overall_contact": {
            "email": "tilmann.schwab@maquet.com", 
            "last_name": "Tilmann Schwab, MD", 
            "phone": "004972229321141"
        }, 
        "overall_contact_backup": {
            "email": "natasa.mitrovic@maquet.com", 
            "last_name": "Natasa Mitrovic"
        }, 
        "overall_official": {
            "affiliation": "Investigational institution", 
            "last_name": "Marco V Ranieri, MD PhD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Not yet recruiting", 
        "oversight_info": {
            "authority": "United States: Institutional Review Board", 
            "has_dmc": "Yes"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "November 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "\u2022\tTo evaluate the clinical effect of PALP\u2122 in reducing the time on invasive ventilation in patients with an exacerbation of COPD requiring invasive mechanical ventilation.", 
            "measure": "Difference in time of mechanical ventilation", 
            "safety_issue": "No", 
            "time_frame": "720 hours"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02107222"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "results_reference": {
            "PMID": "23952848", 
            "citation": "Abrams DC, Brenner K, Burkart KM, Agerstrand CL, Thomashow BM, Bacchetta M, Brodie D. Pilot study of extracorporeal carbon dioxide removal to facilitate extubation and ambulation in exacerbations of chronic obstructive pulmonary disease. Ann Am Thorac Soc. 2013 Aug;10(4):307-14. doi: 10.1513/AnnalsATS.201301-021OC."
        }, 
        "source": "Maquet Cardiopulmonary AG", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Maquet Cardiopulmonary AG", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "June 2014", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "April 2014"
    }
}